EA200901400A1 - Бициклические диазомиметики smac и их применения - Google Patents

Бициклические диазомиметики smac и их применения

Info

Publication number
EA200901400A1
EA200901400A1 EA200901400A EA200901400A EA200901400A1 EA 200901400 A1 EA200901400 A1 EA 200901400A1 EA 200901400 A EA200901400 A EA 200901400A EA 200901400 A EA200901400 A EA 200901400A EA 200901400 A1 EA200901400 A1 EA 200901400A1
Authority
EA
Eurasian Patent Office
Prior art keywords
smac
bicyclic
diazomymetics
application
relates
Prior art date
Application number
EA200901400A
Other languages
English (en)
Other versions
EA017797B1 (ru
Inventor
Шаомэн Ван
Юэфэн Пэн
Хайин Сунь
Цянь Цай
Занета Николовска-Цолеска
Цзяньфэн Лу
Су Цю
Original Assignee
Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39864640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200901400(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган filed Critical Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган
Publication of EA200901400A1 publication Critical patent/EA200901400A1/ru
Publication of EA017797B1 publication Critical patent/EA017797B1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)

Abstract

Изобретение относится к бициклическим диазомиметикам Smac, которые функционируют как ингибиторы ингибитора белков апоптоза. Изобретение также относится к применению этих миметиков для индуцирования апоптотической смерти клетки и для сенсибилизации клеток к индукторам апоптоза.
EA200901400A 2007-04-13 2008-04-14 Бициклические диазомиметики smac, способы их получения, их применения, содержащие их фармацевтические композиции и набор, содержащий указанные композиции EA017797B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92334807P 2007-04-13 2007-04-13
PCT/US2008/060215 WO2008128171A2 (en) 2007-04-13 2008-04-14 Diazo bicyclic smac mimetics and the uses thereof

Publications (2)

Publication Number Publication Date
EA200901400A1 true EA200901400A1 (ru) 2010-04-30
EA017797B1 EA017797B1 (ru) 2013-03-29

Family

ID=39864640

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200901400A EA017797B1 (ru) 2007-04-13 2008-04-14 Бициклические диазомиметики smac, способы их получения, их применения, содержащие их фармацевтические композиции и набор, содержащий указанные композиции

Country Status (23)

Country Link
US (2) US8278293B2 (ru)
EP (1) EP2139490B1 (ru)
JP (1) JP5416089B2 (ru)
KR (1) KR101081685B1 (ru)
CN (1) CN101686981B (ru)
AU (1) AU2008240119B2 (ru)
BR (1) BRPI0810522B8 (ru)
CA (1) CA2683318C (ru)
CY (1) CY1115735T1 (ru)
DK (1) DK2139490T3 (ru)
EA (1) EA017797B1 (ru)
ES (1) ES2504216T3 (ru)
HK (1) HK1141456A1 (ru)
HR (1) HRP20140885T1 (ru)
HU (1) HUE024142T2 (ru)
IL (1) IL201474A (ru)
MX (1) MX2009011069A (ru)
NZ (1) NZ580468A (ru)
PL (1) PL2139490T3 (ru)
PT (1) PT2139490E (ru)
SI (1) SI2139490T1 (ru)
WO (1) WO2008128171A2 (ru)
ZA (1) ZA200907055B (ru)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
WO2007048224A1 (en) 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
MX2009011069A (es) * 2007-04-13 2009-12-03 Univ Michigan Mimeticos de smac diazo biciclicos y usos de los mismos.
EP2491041B1 (en) * 2009-10-23 2017-08-09 The Regents of the University of Michigan Bivalent diazo bicyclic smac mimetics and the uses thereof
KR20120101050A (ko) 2009-11-05 2012-09-12 더 유에이비 리서치 파운데이션 기저형 유전자형 암의 치료 방법
CN102985439B9 (zh) 2010-02-12 2016-08-03 制药科学股份有限公司 Iap bir结构域结合化合物
WO2012052758A1 (en) 2010-10-22 2012-04-26 Astrazeneca Ab Response biomarkers for iap antagonists in human cancers
GB201106817D0 (en) * 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
KR102237888B1 (ko) * 2012-08-23 2021-04-07 더 리젠츠 오브 더 유니버시티 오브 미시간 Iap 단백질의 2가 억제제 및 그를 사용하는 치료 방법
EP2925764B1 (en) 2012-11-30 2023-03-01 Sanford-Burnham Medical Research Institute Inhibitor of apoptosis protein (iap) antagonists
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
AU2013399606B2 (en) 2013-09-09 2016-09-22 Halliburton Energy Services, Inc. Activation of set-delayed cement compositions by retarder exchange
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
US10300074B2 (en) 2014-06-04 2019-05-28 Sanford Burnham Prebys Medical Discovery Institute Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
CA2974367A1 (en) 2015-01-20 2016-07-28 Arvinas, Inc. Compounds and methods for the targeted degradation of the androgen receptor
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
WO2016197114A1 (en) 2015-06-05 2016-12-08 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
WO2017182418A1 (en) 2016-04-20 2017-10-26 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising ripk2 inhibitors
GB201610147D0 (en) 2016-06-10 2016-07-27 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3535265A4 (en) 2016-11-01 2020-07-08 Arvinas, Inc. PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE
FI3689868T3 (fi) 2016-12-01 2023-12-18 Arvinas Operations Inc Tetrahydronaftaleenin ja tetrahydroisokinoliinin johdannaisia estrogeenireseptorin hajottajina
EP3559002A4 (en) 2016-12-23 2021-02-17 Arvinas Operations, Inc. CHEMERICAL MOLECULES TARGETING EGFR PROTEOLYSIS AND RELATED METHODS OF USE
EP3559006A4 (en) 2016-12-23 2021-03-03 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
AU2017382436C1 (en) 2016-12-23 2021-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of Rapidly Accelerated Fibrosarcoma polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
CN117551089A (zh) 2017-01-26 2024-02-13 阿尔维纳斯运营股份有限公司 雌激素受体蛋白水解调节剂及相关使用方法
KR20200072507A (ko) 2017-10-19 2020-06-22 데비오팜 인터네셔날 에스 에이 암 치료를 위한 조합 제품
EP3710443A1 (en) 2017-11-17 2020-09-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
US11028088B2 (en) 2018-03-10 2021-06-08 Yale University Modulators of BTK proteolysis and methods of use
US11161841B2 (en) 2018-04-04 2021-11-02 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
US20200038513A1 (en) 2018-07-26 2020-02-06 Arvinas Operations, Inc. Modulators of fak proteolysis and associated methods of use
EP3831811A4 (en) 2018-07-31 2022-04-20 Fimecs, Inc. HETEROCYCLIC COMPOUND
WO2020041331A1 (en) 2018-08-20 2020-02-27 Arvinas Operations, Inc. Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
KR20240028539A (ko) 2018-09-07 2024-03-05 아비나스 오퍼레이션스, 인코포레이티드 급속 진행형 섬유육종 폴리펩티드의 표적화 분해를 위한 다중 고리 화합물 및 방법
US20220016079A1 (en) 2018-11-26 2022-01-20 Debiopharm International S.A. Combination treatment of hiv infections
US10870663B2 (en) 2018-11-30 2020-12-22 Glaxosmithkline Intellectual Property Development Limited Compounds useful in HIV therapy
JP7504106B2 (ja) 2019-01-17 2024-06-21 デビオファーム・インターナショナル・エス・アー がんの処置のための組合せ物
EP3947368A4 (en) 2019-04-04 2023-01-04 Dana-Farber Cancer Institute, Inc. CDK2/5 DEGRADING AGENTS AND ASSOCIATED USES
CN110028508B (zh) * 2019-05-16 2021-05-28 南京华威医药科技集团有限公司 一种抗肿瘤的重氮双环类细胞凋亡蛋白抑制剂
KR20220035009A (ko) 2019-07-15 2022-03-21 퍼블리크노에 악트시오네르노에 옵스체스트보 "노보시비르스키 자보드 힘콘트센트라토브" (파오 엔제트에이치케이) 원자로 연료 집합체의 제조 방법
CN114867727A (zh) 2019-07-17 2022-08-05 阿尔维纳斯运营股份有限公司 Tau蛋白靶向化合物及相关使用方法
EP4006037A4 (en) 2019-07-31 2023-12-13 Fimecs, Inc. HETEROCYCLIC COMPOUND
AU2020356356A1 (en) 2019-09-25 2022-05-12 Debiopharm International S.A. Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma
AU2021211871A1 (en) 2020-01-20 2022-09-08 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2024022275A1 (zh) * 2022-07-29 2024-02-01 苏州科睿思制药有限公司 Xevinapant的晶型及其制备方法和用途
WO2024054591A1 (en) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
CN118027138A (zh) * 2022-11-07 2024-05-14 南京中澳转化医学研究院有限公司 吡啶酮类化合物及其制备方法、药物组合物和应用
WO2024121395A1 (en) * 2022-12-09 2024-06-13 Debiopharm International Sa Iap inhibitors, methods of making the same and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
EP1425029A4 (en) * 2001-08-10 2006-06-07 Palatin Technologies Inc PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES
WO2005069894A2 (en) 2004-01-16 2005-08-04 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
US7674787B2 (en) * 2004-07-09 2010-03-09 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
WO2006010119A2 (en) 2004-07-09 2006-01-26 Michael Norris Cargo retaining device for use in vehicle cargo storage areas
US8202902B2 (en) * 2006-05-05 2012-06-19 The Regents Of The University Of Michigan Bivalent SMAC mimetics and the uses thereof
AU2007248473B2 (en) * 2006-05-05 2011-01-27 The Regents Of The University Of Michigan Bivalent Smac mimetics and the uses thereof
MX2009011069A (es) * 2007-04-13 2009-12-03 Univ Michigan Mimeticos de smac diazo biciclicos y usos de los mismos.
JP5887134B2 (ja) * 2008-04-11 2016-03-16 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ヘテロアリールによって置換されている二環式のＳｍａｃの模倣物
US8625740B2 (en) * 2011-04-14 2014-01-07 Morpho Detection, Inc. System and method for correcting X-ray diffraction profiles

Also Published As

Publication number Publication date
IL201474A (en) 2015-11-30
WO2008128171A3 (en) 2008-12-11
ES2504216T3 (es) 2014-10-08
US8664212B2 (en) 2014-03-04
BRPI0810522A2 (pt) 2014-10-21
CA2683318A1 (en) 2008-10-23
EA017797B1 (ru) 2013-03-29
HRP20140885T1 (hr) 2014-11-21
CN101686981A (zh) 2010-03-31
KR101081685B1 (ko) 2011-11-09
PT2139490E (pt) 2014-10-08
BRPI0810522B1 (pt) 2020-02-04
EP2139490A4 (en) 2010-10-27
ZA200907055B (en) 2011-03-30
CY1115735T1 (el) 2017-01-25
HK1141456A1 (en) 2010-11-12
KR20100005213A (ko) 2010-01-14
SI2139490T1 (sl) 2014-11-28
IL201474A0 (en) 2010-05-31
JP2010523722A (ja) 2010-07-15
US20100273812A1 (en) 2010-10-28
PL2139490T3 (pl) 2014-11-28
JP5416089B2 (ja) 2014-02-12
EP2139490A2 (en) 2010-01-06
DK2139490T3 (da) 2014-09-08
EP2139490B1 (en) 2014-07-02
CA2683318C (en) 2012-10-30
HUE024142T2 (en) 2016-02-29
BRPI0810522B8 (pt) 2021-05-25
AU2008240119B2 (en) 2012-04-05
NZ580468A (en) 2012-02-24
CN101686981B (zh) 2013-04-10
AU2008240119A1 (en) 2008-10-23
MX2009011069A (es) 2009-12-03
US8278293B2 (en) 2012-10-02
US20120309961A1 (en) 2012-12-06
WO2008128171A2 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
EA200901400A1 (ru) Бициклические диазомиметики smac и их применения
EA200802285A1 (ru) Бивалентные миметики smac и их применения
WO2005069894A3 (en) Conformationally constrained smac mimetics and the uses thereof
WO2006010118A3 (en) Conformationally constrained smac mimetics and the uses thereof
WO2005069888A3 (en) Smac peptidomimetics and the uses thereof
WO2009126947A3 (en) Heteroaryl-substituted bicyclic smac mimetics and the uses thereof
CY1126072T1 (el) Περιοχες gla ως θεραπευτικοι παραγοντες
EA201500172A1 (ru) Модифицированные полипептиды фактора х и их применение
CL2010001637A1 (es) Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras.
GT201400057A (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
EA200601562A1 (ru) Сокристаллы госсипола и их применение
CU23866B1 (es) Peptidomimeticos de smac utiles como inhibidores de proteinas de apoptosis (iap)
ECSP066893A (es) Inhibidores de proteínas de apoptosis (iap)
EA201270257A1 (ru) Производные n1-сульфонил-5-фторпиримидинона
NO20081636L (no) FAP - inhibitorer
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
CL2012002904A1 (es) Combinación o composición farmacéutica que comprende un inhibidor de la señalización de células y/o de la angiogénesis y un inhibidor de la quinasa aurora (aki); kit faramcéutico que la comprende; su uso en el tratamiento de enfermedades oncológicas y fibróticas; y compuestos derivados de indol y pirimidina sustituidos.
EA201270553A1 (ru) Ингибиторы тирозинкиназы брутона
TN2012000485A1 (en) Predictive markers useful in the treatment of fragile x syndrome (fxs)
EA201171494A1 (ru) Миметики белка smac
CL2012002250A1 (es) Compuestos heterociclicos fusionados derivados de pirimidinonas, inhibidores potentes de cdc7; composicion farmaceutica; y su uso en la prevencion o el tratamiento del cancer.
EA201270254A1 (ru) Производные 5-фторпиримидинона
CL2010001426A1 (es) Compuestos derivados de triciclos, inhibidores de la proteina quinasa; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades oncologicas e inmunologicas.
BR112013010834A2 (pt) polipeptídeos fator ix modificados e usos dos mesmos
CL2011002857A1 (es) Compuestos derivados de fenil o heteroaril piridina, inhibidores de sintasa de aldosterona; composicion farmaceutica que comprende un compuesto; combinacion farmaceutica que comprende un compuesto; y uso de los compuestos en el tratamiento de enfermedades cardiovasculares.